Daiichi Sankyo Company, Limited (TYO:4568)
Japan · Delayed Price · Currency is JPY 3,534.00
+64.00 (1.84%)
Jan 8, 2026, 2:34 PM JST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 500.76B JPY in the quarter ending September 30, 2025, with 12.14% growth. This brings the company's revenue in the last twelve months to 1.98T, up 12.56% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
1.98T
Revenue Growth
+12.56%
P/S Ratio
3.25
Revenue / Employee
100.12M
Employees
19,765
Market Cap
6.42T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.89T | 284.57B | 17.77% |
| Mar 31, 2024 | 1.60T | 323.21B | 25.28% |
| Mar 31, 2023 | 1.28T | 233.59B | 22.36% |
| Mar 31, 2022 | 1.04T | 82.38B | 8.56% |
| Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.42T |
| Otsuka Holdings | 2.42T |
| Astellas Pharma | 2.01T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |
| Eisai | 804.39B |
Daiichi Sankyo Company News
- 17 hours ago - Daiichi Sankyo (DSKYF) Partners with GENESIS Pharma for VANFLYTA Distribution - GuruFocus
- 18 hours ago - Daiichi Sankyo, GENESIS Pharma sign VANFLYTA deal in Central and Eastern Europe - Seeking Alpha
- 22 hours ago - Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe - Business Wire
- 16 days ago - AstraZeneca, Daiichi Sankyo's ENHERTU Wins FDA's Breakthrough Therapy Designation In US - Nasdaq
- 16 days ago - ENHERTU Gets Tenth Breakthrough Therapy Designation, Launches Phase 3 Trial In Endometrial Cancer - Nasdaq
- 22 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day Transcript - Seeking Alpha
- 23 days ago - AstraZeneca : ENHERTU Combination Approved In US For 1st-Line HER2-Positive Metastatic Breast Cancer - Nasdaq
- 23 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day - Slideshow - Seeking Alpha